Scholarlink

<p>In the current study, a novel route was established for the synthesis of hybrid benzothiazole derived thiazole bearing <i>bis</i>-thiazolidinone-chalcone (1–15) scaffolds. These compounds were screened for their biological potential as anti-Alzheimer therapeutic agents by inhibiting acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes. The biological evaluation and molecular docking studies revealed that most of the synthesized compounds exhibited significant inhibitory activity against both enzymes, outperforming the standard drug, donepezil. Among them, Analog 15 demonstrated remarkable therapeutic potential, with IC₅₀ values of 3.30 ± 0.70&#xa0;µM and 3.80 ± 0.90&#xa0;µM, as well as strong binding affinities/docking scores of −&#xa0;8.97 and −&#xa0;12.84&#xa0;kcal/mol for AChE and BuChE, respectively. Additionally, enzyme kinetics analysis using Lineweaver–Burk plots confirmed the mode of inhibition of the synthesized analogs. Pharmacokinetic predictions further supported the drug-like properties of these compounds, highlighting favorable pharmacological profiles, including good water solubility, non-carcinogenicity, and biological safety. The findings presented in this study provide compelling evidence for the anti-Alzheimer potential of these novel scaffolds, warranting further investigation through in vivo studies and clinical exploration to assess their full therapeutic applicability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrated insight and in silico investigation of hybrid bis-thiazolidinone derivatives along with anti-Alzheimer activity

  • 期刊论文

  • 发表日期：

    2025年5月17日

查看全文
  • Shoaib Khan,
  • Tayyiaba Iqbal,
  • Mujaddad Ur Rehman,
  • Muhammad Bilal Khan,
  • Mohammad Shahidul Islam,
  • Kholood A. Dahlous

摘要

In the current study, a novel route was established for the synthesis of hybrid benzothiazole derived thiazole bearing bis-thiazolidinone-chalcone (1–15) scaffolds. These compounds were screened for their biological potential as anti-Alzheimer therapeutic agents by inhibiting acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes. The biological evaluation and molecular docking studies revealed that most of the synthesized compounds exhibited significant inhibitory activity against both enzymes, outperforming the standard drug, donepezil. Among them, Analog 15 demonstrated remarkable therapeutic potential, with IC₅₀ values of 3.30 ± 0.70 µM and 3.80 ± 0.90 µM, as well as strong binding affinities/docking scores of − 8.97 and − 12.84 kcal/mol for AChE and BuChE, respectively. Additionally, enzyme kinetics analysis using Lineweaver–Burk plots confirmed the mode of inhibition of the synthesized analogs. Pharmacokinetic predictions further supported the drug-like properties of these compounds, highlighting favorable pharmacological profiles, including good water solubility, non-carcinogenicity, and biological safety. The findings presented in this study provide compelling evidence for the anti-Alzheimer potential of these novel scaffolds, warranting further investigation through in vivo studies and clinical exploration to assess their full therapeutic applicability.